DDAVP

DDAVP (Desmopressin) is a synthetic analog of the natural hormone vasopressin. It is primarily used in the treatment of conditions associated with the deficiency of vasopressin, such as diabetes insipidus, hemophilia A, and von Willebrand disease. DDAVP is also used to manage nocturnal enuresis (bedwetting) in children.

Mechanism of Action

DDAVP works by mimicking the action of vasopressin, a hormone that regulates water balance in the body. It acts on the kidneys to reduce urine production and increase water reabsorption. This helps to concentrate the urine and reduce the frequency of urination. In patients with bleeding disorders, DDAVP stimulates the release of von Willebrand factor and factor VIII, which are essential for blood clotting.

Indications

DDAVP is indicated for:

• Diabetes insipidus: A condition characterized by excessive thirst and excretion of large amounts of severely diluted urine.
• Hemophilia A: A genetic disorder that impairs the body's ability to make blood clots.
• von Willebrand disease: A bleeding disorder caused by low levels of clotting protein in the blood.
• Nocturnal enuresis: Bedwetting in children.

Administration

DDAVP can be administered via various routes, including:

• Intranasal
• Oral
• Intravenous
• Subcutaneous

Side Effects

Common side effects of DDAVP include:

• Headache
• Nausea
• Abdominal pain
• Hyponatremia (low sodium levels in the blood)

Precautions

Patients using DDAVP should be monitored for signs of water retention and hyponatremia. It is important to follow the prescribed dosage and not to exceed the recommended amount to avoid potential complications.

Related Pages

• Vasopressin
• Diabetes insipidus
• Hemophilia A
• von Willebrand disease
• Nocturnal enuresis